Amneal Pharmaceuticals (NASDAQ:AMRX - Get Free Report) issued an update on its FY 2024 earnings guidance on Friday morning. The company provided earnings per share guidance of 0.570-0.630 for the period, compared to the consensus earnings per share estimate of 0.600. The company issued revenue guidance of $2.7 billion-$2.8 billion, compared to the consensus revenue estimate of $2.8 billion.
Wall Street Analyst Weigh In
Several equities analysts have recently issued reports on AMRX shares. JPMorgan Chase & Co. raised shares of Amneal Pharmaceuticals from an "underweight" rating to a "neutral" rating and set a $9.00 price objective on the stock in a research note on Friday, September 6th. Truist Financial upped their target price on Amneal Pharmaceuticals from $10.00 to $12.00 and gave the company a "buy" rating in a report on Wednesday, October 2nd. Finally, Barclays lifted their price target on Amneal Pharmaceuticals from $8.00 to $10.00 and gave the stock an "overweight" rating in a research note on Tuesday, August 13th. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $9.40.
Read Our Latest Research Report on AMRX
Amneal Pharmaceuticals Stock Up 1.4 %
Shares of Amneal Pharmaceuticals stock traded up $0.12 during midday trading on Friday, hitting $8.73. The company's stock had a trading volume of 1,720,274 shares, compared to its average volume of 1,406,196. Amneal Pharmaceuticals has a 1-year low of $3.96 and a 1-year high of $8.95. The firm has a market capitalization of $2.70 billion, a P/E ratio of -14.08 and a beta of 1.17. The stock has a 50-day simple moving average of $8.53 and a 200-day simple moving average of $7.54.
Amneal Pharmaceuticals (NASDAQ:AMRX - Get Free Report) last posted its quarterly earnings results on Friday, August 9th. The company reported $0.15 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.11 by $0.04. Amneal Pharmaceuticals had a negative net margin of 6.72% and a positive return on equity of 1,235.03%. The business had revenue of $701.78 million during the quarter, compared to analyst estimates of $657.43 million. As a group, sell-side analysts predict that Amneal Pharmaceuticals will post 0.52 earnings per share for the current year.
About Amneal Pharmaceuticals
(
Get Free Report)
Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.
See Also
Before you consider Amneal Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amneal Pharmaceuticals wasn't on the list.
While Amneal Pharmaceuticals currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for November 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
